ERIC 2018 | Sequential therapy and drug resistance in CLL in the era of targeted agents

Stephan Stilgenbauer

There have been dramatic advancements in chronic lymphocytic leukemia (CLL) in recent years, including the introduction of a multitude of novel agents, which has opened up a field of new considerations, as discussed here Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany. Prof. Stilgenbauer gives his perspective on drug resistance, and the sequence and combination of therapy, in CLL in this era of novel agents. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Skip to toolbar